Budesonide Monograph: Glucocorticoid Pharmacology, Asthma, GI Formulations and Safety

Evidence-informed pharmacology monograph. Reviewed 10 November 2026. Educational material only; clinical use requires current local product labeling and patient-specific assessment.

Clinical overview

Budesonide is a synthetic glucocorticoid with strong topical anti-inflammatory activity and substantial hepatic first-pass metabolism. Formulations include inhaled suspensions/powders, intranasal sprays, oral modified-release preparations for selected inflammatory bowel conditions, and oral suspension/tablet products for eosinophilic esophagitis. Formulations are not interchangeable: site of release and delivery determine approved indications, doses and systemic exposure [1,2].

Glucocorticoid receptor mechanism

Budesonide binds intracellular glucocorticoid receptors, altering transcriptional regulation and reducing multiple inflammatory pathways including eosinophil recruitment, cytokine signaling and airway edema. Its anti-inflammatory effects unfold over hours to days; inhaled budesonide does not act as an immediate bronchodilator. Improved asthma control is achieved through regular ICS-containing treatment or, in specified combinations, an anti-inflammatory reliever strategy [1,2].

Asthma: inhaled budesonide and budesonide–formoterol

GINA recommends ICS-containing treatment instead of SABA-only approaches in adults/adolescents. Certain low-dose budesonide–formoterol products can provide as-needed anti-inflammatory relief or maintenance-and-reliever therapy (MART), where authorized and appropriately prescribed. This reliever role depends on formoterol, a fast-onset LABA; budesonide alone is a controller and budesonide–salmeterol combinations are not interchangeable with MART regimens. Inhaler device, licensed age and total daily formoterol limits matter [2].

GI disease and other formulations

Enteric-targeted budesonide is used in selected mild-to-moderate Crohn disease involving ileum/right colon; other oral delayed-release products have separate ulcerative colitis indications, and products for eosinophilic esophagitis have specialized administration instructions. These formulations aim to increase local mucosal exposure while limiting, not eliminating, systemic corticosteroid effects. Nasal budesonide treats allergic rhinitis and inhaled/nebulized formulations have age- and product-specific asthma indications [1].

Pharmacokinetics and interactions

Budesonide is absorbed according to route and delivery system, then extensively metabolized via CYP3A4; its low oral systemic bioavailability does not guarantee absence of adrenal effects. Ritonavir, cobicistat, ketoconazole, itraconazole and other strong CYP3A4 inhibitors can increase exposure and cause iatrogenic Cushing syndrome or adrenal suppression. Severe hepatic dysfunction may also increase systemic exposure [1].

Adverse effects, monitoring and counseling

Inhaled budesonide may cause dysphonia and oropharyngeal candidiasis; rinse mouth and spit after use. With prolonged/high-dose or multiple-route exposure, monitor for bone loss, cataracts, glaucoma, infections, growth effects in children and adrenal suppression. Local GI treatment can also cause glucocorticoid adverse effects. Reduce to the lowest effective dose after control, but do not abruptly discontinue long-term systemic steroid therapy [1,2].

References

  1. Brunton LL, Knollmann BC, editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. McGraw Hill; 2023.
  2. Global Initiative for Asthma. Global strategy for asthma management and prevention. 2025 update. Available from: https://ginasthma.org/wp-content/uploads/2025/11/GINA-2025-Update-25_11_08-WMS.pdf
Medical & AI Disclaimer

The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.

We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.

Leave a Reply

Your email address will not be published. Required fields are marked *